Cautious Roche Stresses: 'It's Not Only About APHINITY'
Roche is suddenly sounding less optimistic about its Phase III APHINITY trial of Perjeta in the neoadjuvant breast cancer setting – stressing that 2017 will also bring three other key readouts for the company.
You may also be interested in...
Roche released positive headlines from its APHINITY trial examining use of Herceptin and Perjeta together in the adjuvant treatment of breast cancer, offering promise that its aging oncology franchise can be protected.
Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.
Genentech’s PD-L1 inhibitor Tecentriq could steal market share from the PD-1 inhibitors Opdivo and Keytruda in its new indication, but the Roche subsidiary’s drug is a year behind competitors from Bristol-Myers and Merck in NSCLC with seven Phase III trials under way to expand its reach in lung cancer.